BeiGene dives in on natural killer cells with discovery pact for small biotech's stem cell-based platform
China’s BeiGene has been busy on the oncology front in recent years, looking to keep up with the pack with one late-stage PD-1 on the way to a filing and a slate of small deals fleshing out the pipeline. Now, with its eyes on the horizon, the drugmaker has snared an early-stage pact for a clutch of next-gen cell therapies.
BeiGene will shell out $45 million in cash and an undisclosed amount in future biobucks and royalties for up to four of Shoreline Biosciences’ induced pluripotent stem cell-based natural killer therapies for cancer, the partners said Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.